![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmaceutical-technology.com/news/merz-wins-185m-bid-for-bankrupt-acorda-assets-and-increases-us-workforce-by-50/
https://www.fiercepharma.com/pharma/acorda-inks-185m-asset-deal-merz-therapeutics-files-bankruptcy-after-years-disappointing
https://www.fiercepharma.com/pharma/biogen-returns-ex-us-rights-ms-drug-fampyra-acorda
https://www.pharmatimes.com/news/nice_opts_to_reject_acordas_ms_drug_fampyra_1450334
https://endpts.com/acorda-offloads-manufacturing-operations-to-catalent-for-70m-amid-latest-restructuring-to-keep-the-ship-afloat/
https://www.ema.europa.eu/en/documents/overview/fampridine-accord-epar-medicine-overview_en.pdf
https://www.raps.org/news-and-articles/news-articles/2020/7/ema-thumbs-up-for-11-down-for-2-new-medicines
http://www.pharmatimes.com/news/smc_accepts_four_medicines_for_nhs_use_1338258
https://www.fiercepharma.com/pharma/acorda-backs-way-off-800m-estimate-inbrija-after-lackluster-year
http://www.pharmatimes.com/news/fampyra_recommended_in_wales_after_positive_results_in_ms_1320739
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210158
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210158
http://www.pharmatimes.com/news/smc_endorses_eusa_pharmas_qarziba_1259986
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206646
https://www.prnewswire.com/news-releases/mylan-launches-authorized-generic-of-ampyra-tablets-300716840.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210158
https://www.reuters.com/article/us-acorda-teva-lawsuit/acorda-loses-bid-for-u-s-court-order-halting-generic-ampyra-sales-idUSKBN1KF2BH
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206863
https://www.fiercepharma.com/marketing/win-or-lose-ampyra-acorda-s-reps-are-safe-parkinson-s-prospect
http://www.pharmatimes.com/news/full_green_light_for_biogens_ms_drug_fampyra_1194216
https://www.pharmacompass.com/pdf/news/ampyra-dalfampridine-acorda-therapeutics-inc-v-micro-labs-1496050485.pdf
http://www.fiercepharma.com/pharma/post-patent-court-defeat-acorda-lays-out-plans-to-chop-100-jobs
https://pink.pharmamedtechbi.com/PS120368/Ampyra-Patents-And-The-Perils-Of-Letting-PTAB-Get-Your-Hopes-Up
http://www.fiercepharma.com/pharma/court-nixes-4-acorda-patents-teeing-up-amprya-generics-for-2018
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206811
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206836
http://www.biospace.com/News/investors-upset-as-acorda-abandons-development-of/439798/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.pharmatimes.com/news/smc_endorses_use_of_five_meds_on_nhs_scotland_1175885
http://www.fiercepharma.com/story/sorry-celgene-patent-board-says-bass-can-challenge-your-ip-and-profit-too/2015-09-28?utm_medium=rss&utm_source=rss&utm_campaign=rss
http://www.fiercepharma.com/story/undeterred-pto-setbacks-bass-slaps-new-challenges-acorda-patents/2015-09-04
http://www.fiercepharma.com/story/patent-challenger-bass-shrugs-celgenes-attack-his-short-selling-motives/2015-08-12
http://www.fiercepharmamanufacturing.com/story/attix-pharmaceuticals-recalls-hundreds-apis-us/2015-04-30
http://blogs.wsj.com/pharmalot/2015/04/02/innovate-or-else-kyle-bass-strikes-again-and-challenges-shire-patents/